| 169.975 -1.365 (-0.8%) | 07-31 10:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 214.97 | 1-year : | 229.4 |
| Resists | First : | 184.05 | Second : | 196.41 |
| Pivot price | 169.16  |
|||
| Supports | First : | 164.05 | Second : | 136.49 |
| MAs | MA(5) : | 171.21  |
MA(20) : | 171.97 |
| MA(100) : | 185.09 |
MA(250) : | 178.64 |
|
| MACD | MACD : | -2.9 |
Signal : | -3.4 |
| %K %D | K(14,3) : | 64.1 |
D(3) : | 59.9 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 210.51 | Low : | 144.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AZN ] has closed below upper band by 48.4%. Bollinger Bands are 55.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 172.04 - 172.92 | 172.92 - 173.6 |
| Low: | 167.78 - 168.72 | 168.72 - 169.43 |
| Close: | 169.87 - 171.43 | 171.43 - 172.63 |
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Fri, 31 Jul 2026
AstraZeneca (NASDAQ: AZN) gains EU nod for Datroway in metastatic TNBC - Stock Titan
Fri, 31 Jul 2026
AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer - Seeking Alpha
Thu, 30 Jul 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - PR Newswire
Wed, 29 Jul 2026
AstraZeneca (LSE:AZN) Stock In Focus After Sone Ve Win And Mixed Ultomiris Data - Yahoo Finance
Tue, 28 Jul 2026
AstraZeneca's drug pipeine is splitting opinion among City analysts - Proactive financial news
Mon, 27 Jul 2026
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 68.3 (%) |
| Shares Short | 2,530 (K) |
| Shares Short P.Month | 1,330 (K) |
| EPS | 6.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.55 |
| Profit Margin | 17.1 % |
| Operating Margin | 27.9 % |
| Return on Assets (ttm) | 8.4 % |
| Return on Equity (ttm) | 23.4 % |
| Qtrly Rev. Growth | 12.5 % |
| Gross Profit (p.s.) | 31.78 |
| Sales Per Share | 38.99 |
| EBITDA (p.s.) | 12.92 |
| Qtrly Earnings Growth | 5.3 % |
| Operating Cash Flow | 14,220 (M) |
| Levered Free Cash Flow | 6,560 (M) |
| PE Ratio | 25.53 |
| PEG Ratio | 1.3 |
| Price to Book value | 5.54 |
| Price to Sales | 4.34 |
| Price to Cash Flow | 0 |
| Dividend | 2.15 |
| Forward Dividend | 0 |
| Dividend Yield | 1.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|